Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Aug

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors

Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer

Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer

In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles

cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions